Linked Life Data

11426203

Source:http://linkedlifedata.com/resource/pubmed/id/11426203

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2001-6-26
pubmed:abstractText
Photodynamic therapy is a combination of the systemically injected photosensitizing drug, verteporfin, and the subsequent exposure of the affected retina to a low-beam diode laser. Eligible participants in the photodynamic therapy clinical trial were those with "wet" cases of age-related macular degeneration with subfoveal, predominantly classic lesions. The expected outcome of the treatment is to preserve vision, not to restore lost vision. Study participants are frustrated in their performance of daily activities and often have unrealistic expectations of photodynamic therapy treatment outcomes (eg, improved vision). Frustration and fear are evident at visits during which their actual vision loss is measured. One of our goals is to help the patients have realistic expectations of treatment outcomes.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
N
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1060-135X
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
40-3
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
Psychosocial implications of clinical trials on patients with age-related macular degeneration and pathologic myopia as seen in the photodynamic therapy trials.
pubmed:affiliation
Submacular Surgery Trial, The Wilmer Eye Institute, The Johns Hopkins Hospital, Baltimore, MD 21287, USA.
pubmed:publicationType
Journal Article